Prostate-specific membrane antigen (PSMA) expression in ovarian carcinoma

• Conditions: C56; Malignant neoplasm of ovary

• Registration Number: DRKS00023240
• Lead Sponsor: niversitätsklinikum Freiburg Klinik für Frauenheilkunde

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

Patients with histopathologically confirmed, invasive serous ovarian carcinoma are included in this study.

Exclusion Criteria

missing declaration of consent
other oncological disease
Borderline tumor or other histological subtype (except the invasive serous ovarian carcinoma)
Cytostatic therapy administered before the tissue sample is taken
Radiotherapy performed before the tissue sample is taken

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of the PSMA expression within the ovary and ovarian cancer

Secondary Outcome Measures

Name	Time	Method
Depending on the PSMA status (both tumor cells and tumor novasculature):<br>Survival<br>Disease free survival (dfs)<br>Clinical parameters:<br>- Age at time of diagnosis, menopause status, FIGO stage at diagnosis time, distant metastasis, postoperative chemotherapy.<br>Histopathological parameters:<br>- pTNM stage, lymph node status (pelvic/paraaortal involvement) Grading (low or high grade).